SSR 162369
Alternative Names: SSR-162369Latest Information Update: 18 Jul 2007
Price :
$50 *
At a glance
- Originator sanofi-aventis
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 18 Jul 2007 Discontinued - Phase-I for Type-2 diabetes mellitus in Europe (unspecified route)
- 24 Feb 2006 Phase-I clinical trials in Type-2 diabetes mellitus in Europe (unspecified route)
- 09 Mar 2005 Preclinical trials in Type-2 diabetes mellitus in Europe (unspecified route)